- Home
- HBANL vs VCEL Comparison
HBANL vs VCEL Comparison
Compare HBANL & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HBANL
Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred Stock
Current Price
Company Overview
Basic Information| Metric | HBANL | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | 20242 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | HBANL | VCEL |
|---|---|---|
| Price | $25.57 | $37.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.50 |
| AVG Volume (30 Days) | N/A | ★ 650.6K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $151.57 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | N/A | $29.24 |
| 52 Week High | N/A | $63.00 |
Technical Indicators
Market Signals| Indicator | HBANL | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.45 | 51.30 |
| Support Level | $25.35 | $35.53 |
| Resistance Level | $25.98 | $38.09 |
| Average True Range (ATR) | 0.23 | 1.36 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 34.92 | 70.84 |
Price Performance
Historical ComparisonAbout HBANL Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred Stock
Huntington is a regional US bank with around $208 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.